Us Bancorp \De\ Kinnate Biopharma Inc. Transaction History

Us Bancorp \De\

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$5.26 - $12.19 $10,251 - $23,758	-1,949 Reduced 94.52%	113 $0
Q3 2022 Oct 27, 2022	BUY	$9.86 - $15.76 $818 - $1,308	83 Added 4.19%	2,062 $25,000
Q2 2022 Aug 01, 2022	BUY	$7.43 - $13.0 $7,273 - $12,727	979 Added 97.9%	1,979 $25,000
Q1 2022 May 11, 2022	BUY	$7.73 - $17.99 $7,730 - $17,990	1,000 New	1,000 $11,000
Q4 2021 Feb 11, 2022	SELL	$16.5 - $25.48 $1,650 - $2,548	-100 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$17.81 - $24.87 $890 - $1,243	50 Added 100.0%	100 $2,000
Q2 2021 Aug 05, 2021	BUY	$22.19 - $31.55 $1,109 - $1,577	50 New	50 $1,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.